Instituto de Cardiologia do Rio Grande do Sul Fundação Universitária de Cardiologia Porto AlegreRS Brasil Instituto de Cardiologia do Rio Grande do Sul/Fundação Universitária de Cardiologia, Porto Alegre, RS, Brasil.
Departamento de Ciencias Biomédicas Universidad de León León España Departamento de Ciencias Biomédicas, Universidad de León, León, España.
Arch Endocrinol Metab. 2024 Jul 30;68:e230381. doi: 10.20945/2359-4292-2023-0381. eCollection 2024.
Sulfonylureas have been used to improve performance in strength sports. However, this hypothetical effect has not been proven. We examined the ergogenic acute effect of gliclazide on resistance training performance and muscle recovery.
We conducted a double-blind, randomized, crossover pilot study with 10 healthy resistance-trained adults (29.3 ± 4.4 years), nonusers of anabolic steroids. The participants were randomized to two exercise sessions. In the first session, five participants received placebo and the other five received gliclazide modified release, both administered 8 hours before the session. Session two was performed in a crossover fashion a week later. The volume load was calculated as the maximum number of repetitions of four sets multiplied by load (65% 1-RM). Blood samples were collected before and after exercise, as well as 24 hours and 48 hours after exercise for measurement of creatine kinase (CK-MM) and lactate dehydrogenase (LDH) activity. Blood glucose was measured with a glucometer before, during, and after the exercise sessions.
Gliclazide did not enhance volume load for bench press (placebo: 2,698.0 ± 923.0 kg; gliclazide: 2,675.0 ± 1,088.0 kg; p = 0.073) or leg press (placebo: 10,866.0 ± 2,671.0 kg; gliclazide: 10,817.0 ± 2,888.0 kg; p = 0.135). However, CK-MM (-27.7%; p = 0.034) and LDH (-21.1%; p = 0.021) activities were decreased with gliclazide 48 hours after exercise. There was also a decrease in blood glucose in the gliclazide compared with the placebo session (p = 0.018).
Gliclazide did not enhance performance in a single resistance training session, but promoted faster muscle recovery. The decrease in blood glucose post-exercise with gliclazide was an undesirable effect that could lead to long-term glucose metabolism disorders. Registered in ClinicalTrials.gov under number NCT04443777.
磺酰脲类药物已被用于提高力量运动的表现。然而，这种假设的效果尚未得到证实。我们研究了格列齐特对阻力训练表现和肌肉恢复的急性促进作用。
我们进行了一项双盲、随机、交叉先导研究，纳入了 10 名健康的接受过阻力训练的成年人（29.3±4.4 岁），这些人都没有使用过合成代谢类固醇。参与者被随机分配到两个运动阶段。在第一阶段，五名参与者接受安慰剂，另外五名参与者接受格列齐特缓释片，均在运动前 8 小时服用。第二阶段一周后以交叉方式进行。根据四组的最大重复次数乘以负荷（65%1-RM）计算体积负荷。在运动前后以及运动后 24 小时和 48 小时采集血样，以测量肌酸激酶（CK-MM）和乳酸脱氢酶（LDH）活性。在运动前后使用血糖仪测量血糖。
格列齐特并未增强卧推（安慰剂：2698.0±923.0 kg；格列齐特：2675.0±1088.0 kg；p=0.073）或腿推（安慰剂：10866.0±2671.0 kg；格列齐特：10817.0±2888.0 kg；p=0.135）的体积负荷。然而，运动后 48 小时，CK-MM（-27.7%；p=0.034）和 LDH（-21.1%；p=0.021）的活性降低。与安慰剂相比，格列齐特还降低了运动后的血糖（p=0.018）。
格列齐特在单次阻力训练中并未提高表现，但促进了更快的肌肉恢复。格列齐特运动后血糖降低是一种不良影响，可能导致长期的葡萄糖代谢紊乱。在 ClinicalTrials.gov 上注册，编号为 NCT04443777。
